Quoin Pharmaceuticals (QNRX) Corporate presentation summary

Investment highlights

• Management team with a strong track record and over 90 years of combined experience in drug delivery technologies.

• Clinical trials for Netherton Syndrome underway in the US, EU, and Middle East, with pivotal studies set for 2026.

• Rare Pediatric and Orphan Drug designations received for the lead product, QRX003.

• Nine commercial partnerships outside the US and EU, covering 61 countries and targeting a market opportunity exceeding $1 billion.

• Establishing direct sales infrastructure in the US, EU, and Japan.

Product pipeline and clinical development

• QRX003 targets Netherton Syndrome and Peeling Skin Syndrome, with pivotal clinical studies for Netherton Syndrome to begin in 2026.

• Additional candidates (QRX008, QRX009) address rare dermatological and vascular conditions, with clinical testing for some to commence in 2026.

• Total of 68 subjects tested in QRX003 clinical studies, with ongoing and planned Phase 2 and pivotal trials.

• QRX003 is a topical lotion that mimics the missing LEKTI protein, normalizing skin protease activity and restoring skin barrier function.

• Positive initial clinical data for both Netherton and Peeling Skin Syndromes, including significant improvements in skin symptoms and patient quality of life.

Disease overview and unmet need

• Netherton Syndrome is a rare genetic disorder affecting 6,000–8,000 patients in the US and Europe, with up to 30,000 in partnered territories.

• No approved treatments or cures exist; patients face severe infections, allergies, and frequent hospitalizations.

• Current management requires frequent application of moisturizers and off-label systemic therapies.